Bionano Genomics (BNGO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$30.2M

Revenue (quarter)

$8.2M

Revenue growth (year over year)

+21.36%

Gross profit (trailing twelve months)

$14.3M

Gross margin

47.50%

Net income (trailing twelve months)

−$32.2M

Net income (quarter)

−$7.4M

Net income growth (year over year)

−8.25%

Net margin

−106.58%

Return on equity

−83.56%

EPS (trailing twelve months)

−$3.01

Book value per share

$2.68

P/E (trailing twelve months)

—

Price to book

0.49

Debt to assets

33.59%

Payout ratio

—

Dividend yield

—

Company profile

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

• Is Bionano Genomics (BNGO) profitable?

  No. Bionano Genomics reported a net loss of $32.2M over the trailing twelve months.

• How much revenue does Bionano Genomics (BNGO) make?

  Bionano Genomics generated $30.2M in revenue over the trailing twelve months, up 21.36% year over year.

• How do I buy stock in Bionano Genomics (BNGO)?

  BNGO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.